Unknown PHASE1 INTERVENTIONAL 10-arm NCT05602480

Phase I Clinical Trial of a Candidate PCV13 in Healthy People

Phase I Clinical Trial to Evaluate the Safety and Explore the Immunogenicity of a Candidate PCV13 in Healthy People Aged 2 Months (Minimum 6 Weeks) and Above

Sponsor: Hunan Provincial Center for Disease Control and Prevention

Conditions Pneumococcal Infections

Interventions 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

Updated 4 times since 2022 Last updated: Nov 11, 2022 Started: Nov 1, 2022 Primary completion: Jun 30, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Pneumococcal Infections, this trial is ongoing. The trial is conducted by Hunan Provincial Center for Disease Control and Prevention and has accumulated 4 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

4 versions recorded

Jan 2025 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Dec 2022 — Jul 2024 [monthly]

Recruiting PHASE1

First recorded

Nov 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hunan Provincial Center for Disease Control and Prevention
Liaoning Chengda Biotechnology CO., LTD
Wuhan BravoVax Co., Ltd.

Data source: Wuhan BravoVax Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xiangtan, China